开云app官网登录入口网页版-官方正版

#FOLFOX#

43篇内容 | 1923人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1455479, encodeId=6f7814554e9aa, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, objectType=article, longId=730595, objectId=f470e305957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f470e305957c, replyNumber=0, likeNumber=123, createdTime=2022-06-28, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f470e305957c, moduleTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f470e305957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455478, encodeId=138614554e8ae, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, objectType=article, longId=729659, objectId=add1e2965928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add1e2965928, replyNumber=0, likeNumber=66, createdTime=2022-06-17, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add1e2965928, moduleTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=add1e2965928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455477, encodeId=95ce14554e723, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, objectType=article, longId=729558, objectId=3e05e29558cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e05e29558cc, replyNumber=0, likeNumber=80, createdTime=2022-06-16, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e05e29558cc, moduleTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3e05e29558cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455476, encodeId=a2e714554e65b, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, objectType=article, longId=728685, objectId=6d07e286855f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d07e286855f, replyNumber=0, likeNumber=87, createdTime=2022-06-07, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d07e286855f, moduleTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6d07e286855f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455475, encodeId=56fa14554e512, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, objectType=article, longId=221323, objectId=976a22132323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976a22132323, replyNumber=0, likeNumber=71, createdTime=2021-12-01, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976a22132323, moduleTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=976a22132323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455474, encodeId=fe8c14554e4a7, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, objectType=article, longId=221259, objectId=06bd221259a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bd221259a2, replyNumber=0, likeNumber=75, createdTime=2021-12-01, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bd221259a2, moduleTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=06bd221259a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455473, encodeId=ef1214554e3ca, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Folfoxiri方案在晚期结直肠癌中的应用, objectType=article, longId=220899, objectId=383422089922, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=383422089922, replyNumber=0, likeNumber=51, createdTime=2021-11-25, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=383422089922, moduleTitle=Folfoxiri方案在晚期结直肠癌中的应用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=383422089922)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455472, encodeId=1dd314554e2a3, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=J Clin Oncol：中山大学附属肿瘤医院石明教授团队随机试验证实，采用FOLFOX进行肝动脉灌注化疗可显著延长不可切除的大肝癌患者的生存期！, objectType=article, longId=218768, objectId=3150218e68f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3150218e68f5, replyNumber=0, likeNumber=64, createdTime=2021-10-19, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3150218e68f5, moduleTitle=J Clin Oncol：中山大学附属肿瘤医院石明教授团队随机试验证实，采用FOLFOX进行肝动脉灌注化疗可显著延长不可切除的大肝癌患者的生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3150218e68f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455471, encodeId=46d714554e149, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后, objectType=article, longId=217919, objectId=fd5021e9197a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5021e9197a, replyNumber=0, likeNumber=126, createdTime=2021-10-01, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5021e9197a, moduleTitle=Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fd5021e9197a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455470, encodeId=540314554e065, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！, objectType=article, longId=217215, objectId=63bc21e215a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63bc21e215a3, replyNumber=0, likeNumber=63, createdTime=2021-09-18, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63bc21e215a3, moduleTitle=J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=63bc21e215a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响, objectType=article, longId=209666, objectId=658c209666ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658c209666ea, replyNumber=0, likeNumber=78, createdTime=2021-04-09, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658c209666ea, moduleTitle=JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=658c209666ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455468, encodeId=c8c51455468a2, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, objectType=article, longId=209579, objectId=b43d2095e9ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43d2095e9ba, replyNumber=0, likeNumber=88, createdTime=2021-04-06, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43d2095e9ba, moduleTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b43d2095e9ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455467, encodeId=293c145546e74, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Lancet oncol：3期随机试验| 二线FOLFOX化疗可显著改善晚期胆管癌预后, objectType=article, longId=209416, objectId=24f220941682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24f220941682, replyNumber=0, likeNumber=80, createdTime=2021-04-05, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24f220941682, moduleTitle=Lancet oncol：3期随机试验| 二线FOLFOX化疗可显著改善晚期胆管癌预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=24f220941682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455466, encodeId=52fd1455466ab, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果, objectType=article, longId=207490, objectId=06e320e49013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06e320e49013, replyNumber=0, likeNumber=69, createdTime=2021-02-24, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06e320e49013, moduleTitle=J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=06e320e49013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455465, encodeId=e911145546507, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=60, createdTime=2021-02-11, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455464, encodeId=6f6a145546418, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, objectType=article, longId=202252, objectId=88af2022522e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88af2022522e, replyNumber=0, likeNumber=76, createdTime=2020-10-19, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88af2022522e, moduleTitle=Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=88af2022522e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455463, encodeId=b1601455463f8, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, objectType=article, longId=190232, objectId=9131190232f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9131190232f7, replyNumber=0, likeNumber=66, createdTime=2020-03-19, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9131190232f7, moduleTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9131190232f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455462, encodeId=4856145546276, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, objectType=article, longId=181068, objectId=1eae18106814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eae18106814, replyNumber=0, likeNumber=0, createdTime=2019-10-15, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eae18106814, moduleTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1eae18106814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455461, encodeId=02e1145546178, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=80, createdTime=2019-09-29, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1455460, encodeId=51c51455460a7, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, objectTitle=CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌, objectType=article, longId=158547, objectId=c8d615854e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8d615854e0d, replyNumber=0, likeNumber=63, createdTime=2019-01-22, rootId=0, userName=linlin2314, userId=12f25658567, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8d615854e0d, moduleTitle=CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c8d615854e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

FOLFOX

2020-05-29

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌

2022-06-28

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效

2022-06-17

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌

2022-06-16

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌

2022-06-07

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性

2021-12-01

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗

2021-12-01

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Folfoxiri方案在晚期结直肠癌中的应用

2021-11-25

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

J Clin Oncol：中山大学附属肿瘤医院石明教授团队随机试验证实，采用FOLFOX进行肝动脉灌注化疗可显著延长不可切除的大肝癌患者的生存期！

2021-10-19

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Front Oncol：FOLFOX方案肝动脉灌注化疗(HAIC)联合索拉非尼较单用HAIC改善晚期肝细胞癌的预后

2021-10-01

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

J Clin Oncol：肝切除术后进行mFOLFOX6方案辅助化疗可显著延长仅肝转移的结直肠癌患者的无病生存期！

2021-09-18

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响

2021-04-09

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

2021-04-06

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Lancet oncol：3期随机试验| 二线FOLFOX化疗可显著改善晚期胆管癌预后

2021-04-05

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果

2021-02-24

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Br J Cancer：FOLFOXIRI和贝伐单抗治疗转移性结直肠癌的临床研究汇总分析

2020-10-19

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2020-03-19

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率

2019-10-15

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2019-09-29

linlin2314 (审核中...)

前往app查看评论内容

#FOLFOX#

CLIN CANCER RES：索拉菲尼联合改良FOLFOX治疗晚期肝细胞癌

2019-01-22

科室
- - 订阅+
  - 更多科室
工具
服务